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The emergence of autoimmunity is often cou-
pled with aging, and is suggested to be linked to 
activation of the innate immune system in indi-
viduals suffering from bacterial and viral infec-
tions (Baccala et al., 2007; Groom et al., 2007; 
Krieg and Vollmer 2007; Rothlin et al., 2007). 
Toll-like receptors (TLRs) expressed in leuko-
cytes of the innate immune system play indis-
pensable roles in the sensing of viral and bacterial 
invasion through binding pathogen-associated 
molecular patterns, which leads to efficient T 
cell–mediated inflammatory responses (Akira   
et al., 2001; Iwasaki and Medzhitov, 2004). The 
TLR-mediated priming of inflammation and 
production of neutralizing antibodies against 
pathogens should be strictly regulated, otherwise 
there is the possibility of the development of au-
toimmune diseases (Marsland and Kopf, 2007). 
The mechanisms underlying the efficient TLR-
mediated activation of the innate and adaptive 
immune systems with prevention of reactivity to 
autologous tissues remain elusive.
Examples of critical cells that express TLRs 
and could potentially link the innate and adap-
tive immune systems are relatively primitive   
B cells, B-1 cells, found mainly in the peritoneal 
and pleural cavities. In contrast to recirculating 
follicular  B  cells  (or  conventional  B  or  B-2 
cells), B-1 cells are characterized by B220lowIg
MhighCD23CD43+IgDlow  cells  (Berland  and 
Wortis, 2002; Tung and Herzenberg, 2007). 
Although it has been pointed out by many re-
searchers that innate B-1 cells but not conven-
tional B cells are producers of natural antibodies 
against  pathogens  (Ochsenbein  et  al.,  1999), 
accumulating lines of evidence suggest that   
a major source of autoantibodies is also those   
B-1 cells (Baumgarth et al., 2005; Carroll and   
Holers, 2005), but it has been a matter of debate. 
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Pathogens are sensed by Toll-like receptors (TLRs) expressed in leukocytes in the innate 
immune system. However, excess stimulation of TLR pathways is supposed to be connected 
with provocation of autoimmunity. We show that paired immunoglobulin (Ig)-like receptor 
B (PIR-B), an immunoreceptor tyrosine-based inhibitory motif–harboring receptor for major 
histocompatibility class I molecules, on relatively primitive B cells, B-1 cells, suppresses 
TLR9 signaling via Bruton’s tyrosine kinase (Btk) dephosphorylation, which leads to attenu-
ated activation of nuclear factor B p65RelA but not p38 or Erk, and blocks the produc-
tion of natural IgM antibodies, including anti-IgG Fc autoantibodies, particularly 
rheumatoid factor. The autoantibody production in PIR-B–deficient (Pirb/) mice was 
further augmented in combination with the Faslpr mutation, which might be linked to the 
development of autoimmune glomerulonephritis. These results show the critical link be-
tween TLR9-mediated sensing and a simultaneously evoked, PIR-B–mediated inhibitory 
circuit with a Btk intersection in B-1 cells, and suggest a novel way toward preventing 
pathogenic natural autoantibody production.
© 2009 Kubo et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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B-1 cells, such as through down-regulation of Btk activation 
or enhancement of PIR-B–mediated B-1 cell regulation.
RESULTS
PIR-B deficiency with Faslpr mutation characteristically 
augments autoantibody production associated  
with autoimmune glomerulonephritis
Pirb/ mice were grossly normal and survived well to at least 
50 wk of age (Fig. 1 A) without any abnormalities in the histology 
of their joint components (synovium and cartilage; Fig. S1 A), 
skin, lungs, and glomeruli (not depicted). However, Pirb/Faslpr 
mice were found to be markedly short-lived, with only about 
half of them surviving at 40 wk of age (Fig. 1 A). Microscopic 
examination of their organ samples revealed that the combined 
mutant mice did not develop histopathological traits in the lung, 
salivary glands (not depicted), and joints (Fig. S1 A), but that in 
the kidney they readily developed diffuse glomerulopathy with 
a mild increase in the size and cellularity (mesangial area) of the 
glomerulus (Fig. 1 B, periodic acid–Schiff [PAS] stain). Immuno-
fluorescence analysis revealed substantial deposition of IgG, 
IgM, and C3 in Pirb/Faslpr mice (Fig. 1 B). These pathological 
changes were not observed in wild-type B6 or Faslpr mice, indi-
cating that autoimmune glomerulonephritis occurs as a com-
bined effect of PIR-B and Fas mutations (Fig. S1 B). Consistent 
with no arthritis and Sjögren-like disease in the double-mutant 
mice, anti–SS-B/La antibodies were below the detection limit 
(Fig. S1 C, left). We also found that, although the levels of IgM- 
and IgG-RF were high in Faslpr mice, these levels were further 
elevated in Pirb/Faslpr mice (Fig. 1 C), indicating that PIR-B 
deficiency has a marked impact on the augmentation of RF 
production in vivo. In addition, anti–double-stranded (ds) DNA 
autoantibody production was more augmented in Pirb/Faslpr 
mice than in Faslpr animals, although the difference did not reach 
a statistically significant level (Fig. 1 D). We also measured by 
ELISA the levels of autoantibodies in sera against single-stranded 
(ss) DNA and 2–glycoprotein I (2-GPI), but we did not   
observe a significant elevation of anti-ssDNA production in 
Pirb/Faslpr mice tested compared with Faslpr animals (Fig. 1 D, 
right), nor we did not detect anti–2-GPI (Fig. S1 C, right). 
Examinations of hematocrit values failed to demonstrate an au-
toimmune hemolytic anemia in Pirb/Faslpr and other mice 
(Table S1). The PIR-B deficiency did not result in any obvious 
changes in the staining pattern by antinuclear autoantibodies 
(Fig. S1 D). The peritoneal B-1 cell (Fig. 1 E, top) and splenic 
plasma cell (Fig. 1 E, bottom) populations were also markedly 
increased in Pirb/Faslpr mice. With these data collectively, we 
concluded that PIR-B deficiency renders mice susceptible to 
the development of autoimmune glomerulonephritis in combi-
nation with Faslpr, which accompanies with a markedly elevated 
RF production, with a robust production of anti-dsDNA and 
anti-ssDNA autoantibodies.
Elevated RF production in Pirb/ mice administered  
with CpG-B DNA
RF is one of the autoreactive natural antibodies whose primary 
role is believed to be the first-line defense against infection. 
By stimulation via different TLRs, the B-1 cell population in 
the peritoneal cavity has been enlarged and B-1 cell–mediated 
autoantibody production augmented (Murakami et al., 1995). 
This could be partly because B-1 cells express a set of TLRs, 
including TLR4, TLR7, and TLR9 (Gururajan et al., 2007), 
and are more prone to differentiate into plasma cells than   
B-2 cells upon TLR-mediated stimulation, although B-2 cells 
similarly possess a range of TLRs (Genestier et al., 2007). For 
example, Murakami et al. (1995) have shown, in anti–red 
blood cell autoantibody transgenic mice, that the susceptibil-
ity to autoimmune hemolytic anemia was significantly in-
creased when the mice were transferred from germ-free or 
specific pathogen-free conditions to conventional conditions 
or injected with a TLR4 ligand, LPS, with a concomitant in-
crease in the peritoneal B-1 cell population, whereas almost 
all B-2 cells are constitutively deleted in the transgenic mice. 
These findings again suggest the importance of the regulation 
of TLR signaling in B-1 cells, which prevents overstimulation 
of TLRs so as not to evoke overproduction of natural anti-
bodies, including potentially harmful autoantibodies. There-
fore, what mechanisms may regulate the overstimulation of 
the TLR signal, particularly in B-1 cells?
We speculated that paired Ig-like receptor B (PIR-B; 
Hayami et al., 1997; Kubagawa et al., 1997) could participate 
in the regulation of B-1 cells. Recruitment of SH2 domain–
containing tyrosine phosphatase 1 (SHP-1) to phosphotyro-
sylated immunoreceptor tyrosine-based inhibitory motifs 
(ITIMs) in the cytoplasmic portion of PIR-B was shown to 
be critical for PIR-B–mediated inhibitory signaling in gen-
eral (Ho et al., 1999; Maeda et al., 1999), and this inhibition 
is achieved, at least in part, via constitutive binding of PIR-B 
to its ligand, i.e., MHC class I molecules, expressed on the 
same cell surface (Masuda et al., 2007). Interestingly, in PIR-
B–deficient (Pirb/) mice, the peritoneal B-1 cell popula-
tion significantly increased, particularly with aging, compared 
with wild-type mice (Ujike et al., 2002). However, it has not 
been determined how the B-1 cell compartment is physio-
logically regulated by PIR-B or what the physiological or 
pathological consequence of the expanded B-1 cells is in the 
contexts of infection and autoimmunity.
In this paper, we show that PIR-B can inhibit TLR9-
mediated signaling via regulation of Bruton’s tyrosine kinase 
(Btk) phosphorylation in peritoneal B-1 cells. We found that 
TLR9 activation immediately activates an Src family kinase, 
Lyn, which then phosphorylates PIR-B cytoplasmic ITIMs. 
In the absence of PIR-B, B-1 cells become hyperproducers 
of natural IgM antibodies, including anti-IgG Fc autoanti-
bodies, i.e., rheumatoid factor (RF), via unmethylated CpG-
B oligodeoxynucleotide (CpG-B) stimulation in vitro and in 
vivo or upon aging. These phenotypes caused by PIR-B de-
ficiency were further exaggerated in combination with the 
Faslpr mutation, which caused the Pirb/Faslpr mutant mice 
to be short-lived mainly because of autoimmune glomerulo-
nephritis with immune complex depositions. Our findings 
may provide a novel strategy for preventing autoimmunity 
by reducing the production of pathogenic autoantibodies by JEM VOL. 206, August 31, 2009 
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mune diseases, which are otherwise evoked by too strong or 
sustained innate responses against microbial or viral infections 
(Murakami et al., 1995; Akira et al., 2001; De Re et al.,   
2006; Krieg and Vollmer, 2007; Marsland and Kopf, 2007). To 
The main source of such autoantibodies is considered to be B-
1 cells (Montecino-Rodriguez and Dorshkind, 2006). Ade-
quate regulation of the production of natural autoantibodies, 
including RF, is proposed to be crucial for avoiding autoim-
Figure 1.  Pirb/ with the Faslpr mutation is sufficient in mice for the development of glomerulonephritis with marked elevation of RF pro-
duction. (A) Pirb/Faslpr mice were remarkably short-lived. The survival curves for male and female B6.Pirb/Faslpr (n = 20 mice per group), B6.Faslpr  
(n = 20), B6.Pirb/ (n = 20), and B6 (n = 20) mice until 50 wk of age are shown. (B) Pirb/Faslpr mice develop diffuse glomerulonephritis with a mild  
increase in the size and cellularity of the glomerulus, and depositions of IgG, IgM, and complement C3. Kidney sections from each strain of mice at 24 wk 
of age were stained with PAS or Alexa Fluor 488 anti–mouse IgG, IgM, and C3. Each panel is representative of samples from five mice per group with similar 
staining profiles in a single staining experiment. Bars, 10 µm. (C) Both the IgM- and IgG-RF levels were significantly more elevated in Pirb/Faslpr mice 
than those in Faslpr mice. RF in sera from each strain of mice at 24 wk of age was measured by ELISA. Data are shown as means ± SEM (n = 8 mice per 
group) and are representative of three separate experiments with similar results. Statistical analyses were performed using a Student’s t test. *, P < 0.05; 
**, P < 0.01. (D) The anti-dsDNA and anti-ssDNA autoantibody levels were augmented but not significantly elevated in the Pirb/Faslpr mice tested com-
pared with Faslpr mice. Anti-DNA in sera from each strain of mice at 24 wk of age for anti-dsDNA or at 4–10 mo of age for anti-ssDNA was measured by 
ELISA. Data are shown as means ± SEM (n = 8 mice per group) and are representative of three (anti-dsDNA) or two (anti-ssDNA) separate experiments 
with similar results. Statistical analyses were performed using a Student’s t test. *, P < 0.05; **, P < 0.01. (E) Markedly enlarged peritoneal B-1 cell and 
splenic plasma cell populations in Pirb/Faslpr mice. Peritoneal cells isolated from 24-wk-old mice were stained with anti-B220, CD5, and CD3. 
B220+CD5+CD3 B-1 cells (circled) with the percentages are shown (top). Staining of peritoneal cells from Pirb/ mice with anti-CD19, instead of B220, 
gave a B-1 cell population with a similar size (not depicted in the figure). Splenocytes isolated from 24-wk-old mice were stained with anti-CD138, B220, 
IgM, and IgD. CD138+B220+IgMIgD plasma cells (circled) with the percentages are shown (bottom). The figure is representative of five mice per group.1974 PIR-B REGULATES TLR9-INDUCED BTK–NF-B CASCADE | Kubo et al.
characterize the precise sources of RF, we next examined the 
RF levels in sera from B6 and Pirb/ mice in the absence 
of a potentially large influence by Faslpr mutation. Although 
8- and 40-wk-old B6 wild-type mice did not show notable 
production of either IgM-RF or IgG-RF, Pirb/ mice at 
40 wk of age exhibited significantly higher levels of IgM-
RF and slightly elevated IgG-RF levels (Fig. 2 A). When 
we intraperitoneally injected 3 nmol CpG-B DNA, a ligand 
for TLR9, into 8-wk-old B6 and Pirb/ mice, and deter-
mined IgM-RF and IgG-RF levels in their sera after 48 and 
120 h, respectively, we found that the RF of both classes 
was significantly elevated in Pirb/ but not in B6 mice   
(Fig. 2 B), suggesting that CpG-B–responsive cells in the 
peritoneal cavity produce RF. Diminishing B-1 cells, as 
well as B-2 cells, in the peritoneum by repeated injection of 
water (Fig. S2; Murakami et al., 1995) resulted in a signifi-
cant reduction of the total IgM level and a nearly complete 
abrogation of IgM-RF production in Pirb/ mice compa-
rable to that in wild-type mice (Fig. 2 C). These results sug-
gest that peritoneal B cells are a major source of IgM-RF 
autoantibodies in Pirb/ mice.
Augmented CpG-B responses in PIR-B–deficient B-1  
cells in vitro
Next, we aimed at examining more precisely the PIR-B–
mediated regulation of RF production by B-1 cells in vitro. We 
sorted B220+CD11b+ B-1 cells from peritoneal cells of B6 and 
Pirb/ mice, and examined them for their proliferation upon 
stimulation with various TLR ligands. B-1 cells from both B6 
and Pirb/ mice were found to respond well to LPS (TLR4 
ligand) and CpG-B (TLR9 ligand), but not to poly(I:C) (TLR3 
ligand) or ssRNA (TLR7/8 ligand; Fig. 3 A), indicating the 
significant roles of TLR4 and TLR9 in the B-1 cell function, 
as pointed out previously (Gururajan et al., 2007). Interest-
ingly, however, stimulation of Pirb/ B-1 cells with CpG-B 
provoked higher proliferation than that of wild-type cells, 
whereas the LPS-mediated responses were comparable. The 
CpG-B–mediated  augmented  proliferation  seen  for  Pirb/  
B-1 cells was not observed for splenic B-2 cells (Fig. 3 B, left), 
as in the case of LPS (Fig. 3 B, right). These results indicate that 
Pirb/ peritoneal B-1 cells, but not the splenic B-2 cells, were 
more sensitive to CpG-B stimulation and divided more vigor-
ously than those from wild-type mice. We observed that B-1 
cells express about sixfold more PIR-B molecules on their sur-
face than splenic B-2 cells, whereas the TLR9 expression levels 
are comparable between B-1 and B-2 cells when estimated by 
flow cytometry (Fig. S2, A and B). We also noted that the ex-
pression level of Btk, one of the signal mediators downstream 
of PIR-B (Maeda et al., 1999), is higher in B-1 cells than that 
in B-2 cells (Fig. S3, C and D). These observations may ac-
count for, at least partly, the difference in the sensitivity to 
CpG-B between B-1 and B-2 cells.
This observation of CpG-B–sensitive Pirb/ B-1 cells 
prompted  us  to  examine  whether  other  possible  B-1  cell 
products (Baumgarth et al., 2005; Carroll and Holers, 2005; 
Gururajan et al., 2007) could also be elevated. A culture   
Figure 2.  Enhanced RF production in Pirb/ mice. (A) The IgM-RF 
levels are significantly elevated in Pirb/, aged mice in particular. Sera 
from wild-type B6 and Pirb/ mice at 8 and 40 wk of age were subjected 
to measurement of the IgM- and IgG-RF levels by ELISA. Data are shown 
as means ± SEM (n = 5 mice per group) and are representative of three 
separate experiments with similar results. Statistical analyses were per-
formed using a Student’s t test. *, P < 0.05. (B) Both the IgM- and IgG-RF 
levels in sera were elevated in Pirb/ mice after CpG-B administration 
into the peritoneum of the animals. B6 and Pirb/ mice at 8 wk of age 
were injected with 3 nmol CpG-B into the peritoneal cavity. Serum sam-
ples collected after 48 and 120 h were analyzed by ELISA for IgM- and 
IgG-RF, respectively. Data are shown as means ± SEM (n = 4 mice per 
group) and are representative of three separate experiments with similar 
results. Statistical analyses were performed using a Student’s t test. *, P < 
0.05. (C) IgM-RF is produced preferentially by peritoneal B cells. B6 and 
Pirb/ mice at 5 wk of age were injected intraperitoneally with water or 
PBS as a negative control to achieve relatively specific elimination of the 
B-1 cells (Murakami et al., 1995). After four rounds of water injection, the 
total IgM level was significantly decreased and the IgM-RF was substan-
tially lost in sera from Pirb/ mice. Data are shown as means ± SEM (n = 
3 mice per group) and are representative of three separate experiments 
with similar results. Statistical analyses were performed using a Student’s 
t test. *, P < 0.05.JEM VOL. 206, August 31, 2009 
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Figure 3.  Enhanced responses in peritoneal B-1 cells from Pirb/ mice upon CpG-B stimulation in vitro. (A and B) Proliferation of peritoneal 
B-1 cells (A) or splenic B-2 cells (B) from wild-type B6 and Pirb/ mice (n = 5 per group) with various stimuli. Peritoneal B-1 cells and splenic B-2 cells 
were pulse labeled with [3H]thymidine during the last 8 h of the 48-h culture period with or without a stimulant. Data are shown as means ± SEM of 
triplicate cultures and are representative of three independent experiments. Statistical analyses were performed using two-way analysis of variance.  
***, P < 0.001. (C) Production of Igs, autoantibodies, and a cytokine by peritoneal B-1 cells from B6 and Pirb/ mice (n = 5 per group). B-1 cells were 
stimulated with 1 µM CpG-B or GpC control, and assessed for total IgM, IgM-RF, IgG-RF, anti-dsDNA, and IL-10 by ELISA. Data are shown as means ± 
SEM of triplicate cultures, and are representative of three independent experiments. Statistical analyses were performed using a Student’s t test. ***, P < 
0.001. Provided standard and assay diluent supplemented in the ELISA kit were served as positive control (Pc) and negative control (Nc), respectively.1976 PIR-B REGULATES TLR9-INDUCED BTK–NF-B CASCADE | Kubo et al.
cells or cultured macrophages, which give a grossly similar 
PIR-B signal upon CpG-B stimulation as B-1 cells (unpub-
lished data), in some analyses of signaling events. PIR-B 
phosphorylation in peritoneal cells was augmented, reached 
a maximum as early as 5 min after CpG-B addition, and 
lasted for at least 20 min (Fig. 4 A). Notably, PIR-B in peri-
toneal cells in the nonstimulated state was already tyrosine 
phosphorylated, as in the cases of other cells such as splenic 
B cells and macrophages (Fig. 4, B and C, B-1 cells and mac-
rophages, respectively; Ho et al., 1999; Kubagawa et al., 
1999; Maeda et al., 1999), possibly because of constitutive 
PIR-B ligation to MHC class I molecules on the same cell 
surface (Masuda et al., 2007). CpG-B–induced augmenta-
tion of PIR-B phosphorylation indeed also occurred in puri-
fied B-1 cells 5 min after the stimulation, and was accompanied 
by a significant increase in SHP-1 recruitment (Fig. 4 B). 
Importantly, although we also found augmented phosphoryla-
tion of PIR-B and enhanced recruitment of SHP-1 upon 
stimulation of cultured macrophages with CpG-B, but not 
GpC control DNA (Fig. 4 C, left), these events were not 
observed in TLR9-deficient cells (Fig. 4 C, right), indicating 
that CpG-B–mediated PIR-B phosphorylation is dependent 
supernatant was collected after a 20–72-h stimulation of B-1 
cells with 1 µM CpG-B, which was subjected to measure-
ment of the contents of autoantibodies and a cytokine by 
ELISA (Fig. 3 C). We found that total IgM, IgM-RF, and 
IL-10 release, but not IgG-RF or anti-dsDNA, were signifi-
cantly more elevated in Pirb/ B-1 cells than in wild-type 
cells. Collectively, these data indicate that CpG-B stimula-
tion of Pirb/ peritoneal B-1 cells resulted in augmented 
proliferation, enhanced IgM antibody production (including 
autoreactive IgM-RF), and IL-10 release in vitro. Although 
B-1 cells express PIR-B molecules more abundantly on their 
surface than splenic B-2 cells (Fig. S3 A), the expression of 
PIR-A, an activating counterpart of PIR-B, is not detected 
on B-1 cells (Fig. S4, A and B), and the TLR9 level is not 
augmented in Pirb/ B-1 cells (Fig. S4 C), suggestive of the 
presence of any PIR-B–mediated inhibitory signaling that 
specifically regulates TLR9 in B-1 cells.
Augmented phosphorylation of PIR-B and SHP-1 
recruitment upon CpG-B stimulation of B-1 cells
Because of the very limited number of purified B-1 cells that 
we can sort from peritoneal cells, we used whole peritoneal 
Figure 4.  Augmented phosphorylation of PIR-B and enhanced recruitment of SHP-1 in peritoneal B-1 cells stimulated with CpG-B. (A) Time 
course of tyrosine phosphorylation of PIR-B in peritoneal cells from B6 and Pirb/ mice (n = 8 per group) stimulated with CpG-B. After stimulation with  
1 µM CpG-B, samples were taken at various time points and first immunoprecipitated (IP) with anti–PIR-B and then immunoblotted (IB) to visualize PIR-B 
phosphotyrosine (top), followed by reprobing with anti–PIR-B (bottom). Data are representative of three separate experiments with similar results. (B) Aug-
mented tyrosine phosphorylation of PIR-B and enhanced recruitment of SHP-1 in peritoneal B-1 cells stimulated with CpG-B. B-1 cells from wild-type B6 
mice (n = 12) were stimulated with 1 µM CpG-B and subjected to immunoprecipitation and protein blot analysis (IP-Western) to visualize the phosphotyro-
sylation of PIR-B (top), SHP-1 (middle), and PIR-B (bottom). Data are representative of three separate experiments with similar results. (C) Phosphotyrosyl-
ation of PIR-B upon CpG stimulation is dependent on TLR9. Bone marrow–derived cultured macrophages (BMMs) from wild-type B6 mice (left) and 
TLR9-deficient (Tlr9/) mice (right; n = 4 per group) were stimulated with 1 µM CpG-B or GpC control DNA, and subjected to IP-Western to visualize phos-
photyrosylated PIR-B (top), SHP-1 (second from top), Lyn (second from bottom; arrow), and PIR-B (bottom). Data are representative of three separate experi-
ments with similar results. The intensity for each band was estimated by densitometric scanning with normalization as to loading control.JEM VOL. 206, August 31, 2009 
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Enhanced activation of NF-B but not the mitogen-
activated protein kinase (MAPK) pathway in PIR-B–
deficient B-1 cells after CpG-B stimulation
Next we aimed at elucidating the molecular events occurring 
in two major downstream cascades of TLR9 activation upon 
CpG-B stimulation of Pirb/ B-1 cells. Generally, TLR9-
mediated signaling leads to activation of NF-B as well as the 
MAPK pathway (Akira et al., 2001; Baccala et al., 2007; 
Krieg and Vollmer, 2007). We observed that the phosphoryla-
tion levels of p38 MAPK and Erk were significantly aug-
mented, particularly at 30 min after CpG-B addition, in both 
wild-type and Pirb/ B-1 cells (Fig. 6, A–C). However, the 
phosphorylation kinetics and levels were comparable between 
these cells, suggesting that these phosphorylation events are 
independent of PIR-B–mediated regulation. Interestingly, how-
ever, p65 NF-B phosphorylation was found to be markedly 
augmented in Pirb/ B-1 cells as early as 5 min after CpG-B 
addition (Fig. 6, A and D). These results indicate that the 
NF-B p65RelA subunit could be the target molecule lo-
cated the most downstream of regulation through Lyn-medi-
ated PIR-B phosphorylation, whereas the MAPK pathway is 
not linked to the PIR-B pathway.
Btk can link the PIR-B pathway and NF-B cascade
Which molecule acts as an intersection between the PIR-B–
SHP-1–initiated inhibitory signaling pathway and the TLR9–
NF-B cascade? Maeda et al. (1999) reported that, in a B cell 
on TLR9. Interestingly, stimulation of macrophages with 
CpG-B but not GpC induced coprecipitation of PIR-B and 
Lyn, whereas the stimulation of TLR9-deficient macro-
phages did not (Fig. 4 C, second from bottom), suggestive of 
an interaction of Lyn and PIR-B upon TLR9 activation (see 
following paragraph).
Up-regulated phosphorylation of PIR-B is mediated,  
at least partly, by Lyn
Preceding studies by others indicated that, in splenic B cells, 
Lyn is the major Src family kinase that constitutively phos-
phorylates PIR-B (Ho et al., 1999). To elucidate the mo-
lecular  mechanisms  underlying  TLR9-mediated  PIR-B 
phosphorylation, we first examined activation of Lyn in TLR9-
sufficient or -deficient B-1 cells stimulated with CpG-B. 
The phosphorylation level of Lyn was found to be aug-
mented as early as 5 min after CpG-B stimulation of B-1 
cells regardless of the presence or absence of PIR-B (Fig. 5, 
A and B). However, augmented phosphorylation of Lyn 
was not observed in TLR9-deficient B-1 cells (Fig. 5,   
C and D). In addition, as noted in the previous paragraph, 
Lyn–PIR-B coprecipitation was detected in a macrophage 
lysate prepared after stimulation with CpG-B (Fig. 4 C, sec-
ond from bottom). These results indicate that Lyn is rapidly 
activated downstream of TLR9 and strongly suggest that 
Lyn is a candidate, if not the sole, Src family kinase that 
phosphorylates PIR-B.
Figure 5.  Up-regulated phosphorylation of Lyn upon CpG-B stimulation of wild-type and Pirb/ B-1 cells but not Tlr9/ cells.  
(A and B) Peritoneal B-1 cells from wild-type B6 and Pirb/ mice (n = 12 per group) were stimulated with 1 µM CpG-B and subjected to IP-Western 
analysis to visualize the phosphprylated Lyn (A). The phosphorylation levels of Lyn were estimated by densitometric scanning with normalization as to 
loading control and are depicted as a bar graph (B). Lyn phosphorylation was augmented upon CpG stimulation regardless of the presence or absence of 
PIR-B. Data are shown as means ± SEM of three separate experiments. (C and D) Peritoneal B-1 cells from wild-type B6 and Tlr9/ mice (n = 12 per 
group) were stimulated with 1 µM CpG-B and subjected to IP-Western analysis to visualize the phosphorylated Lyn (C). The phosphorylation levels of Lyn 
were estimated by densitometric scanning with normalization as to loading control and are depicted as a bar graph (D). Augmented Lyn phosphorylation 
was not observed in Tlr9/ B-1 cells. Data are shown as means ± SEM of three separate experiments. Control bands of Lyn (56 kD) were obscured by 
40–60-kD diffuse bands originated from protein A released from immunoprecipitation beads. *, P < 0.05.1978 PIR-B REGULATES TLR9-INDUCED BTK–NF-B CASCADE | Kubo et al.
observed that a slight increase in the phosphorylation level of 
Btk 5 min after CpG-B stimulation was partially blocked by 
pretreatment with the inhibitors (Fig. 8, A and B). The re-
duction of the phosphorylation was more evident in the case 
of NF-B p65RelA (Fig. 8, A and C). These results indicate 
that Btk phosphorylation is dependent, at least partly, on an 
Src family kinase, most likely Lyn, and that NF-B p65RelA 
phosphorylation is also a critical event downstream of Src 
family kinase activation.
DISCUSSION
Recent studies have suggested several feedback regulators for 
TLR9 activation, including SOCS1 (Rothlin et al., 2007), 
ATF3 (Whitmore et al., 2007), IRF-4 (Martin et al., 2007), 
and SHP-1 (An et al., 2008). For example, receptor tyrosine-
based activation motif–induced, SOCS1-mediated feedback 
regulation seems to occur at later stages, such as hours, after 
TLR9 activation, followed by inflammatory cytokine induc-
tion (Rothlin et al., 2007). In contrast, the PIR-B–mediated 
suppression revealed in this study seems to take place as early 
as 5 min after CpG-B addition to B-1 cells. Therefore, PIR-B 
does not seem to fit well into the category of feedback regu-
latory elements for TLR9. Rather, it plays an important reg-
ulatory role in immediate-early cellular responses to TLR9 
line, IIA1.6, Syk, and Btk were the substrates for SHP-1 re-
cruited to PIR-B ITIMs upon stimulation of B cell receptors. 
This observation prompted us to examine the possible in-
volvement of these two molecules in the TLR9 pathway. Ex-
amination of the phosphorylation status of Syk upon CpG-B 
addition to B-1 cells did not reveal significant enhancement 
of the phosphorylation in either wild-type or Pirb/ B-1 cells 
(Fig. 7, A and B), indicating that Syk does not seem to be a 
critical substrate for SHP-1 recruited to PIR-B ITIMs in B-1 
cells. Instead, we found that Btk phosphorylation was mark-
edly augmented 5 min after CpG-B addition in both wild-
type and Pirb/ B-1 cells, and the augmentation did not 
show a marked decrease at least up to 30 min after CpG-B 
stimulation in Pirb/ B-1 cells (Fig. 7, A and C), indicating 
that Btk is a major substrate for SHP-1.
Pretreatment of B-1 cells with Src family kinase inhibitors 
can suppress phosphorylation of Btk and NF-B p65RelA 
after CpG-B stimulation
To verify that Lyn could be the most upstream effector for 
Btk and NF-B p65RelA phosphorylation, wild-type B-1 cells 
were pretreated with Src family kinase inhibitors (SU6656 or 
PP2), stimulated with CpG-B, and examined to determine 
the phosphorylation levels of Btk and NF-B p65RelA. We 
Figure 6.  p38 and Erk phosphorylation is not grossly influenced by PIR-B, whereas NF-B p65RelA phosphorylation is markedly augmented 
in Pirb/ B-1 cells. (A–D) Immunoblot analysis of phospho-p38, phospho-Erk, and phospho-p65RelA after CpG stimulation of peritoneal B-1 cells from 
wild-type B6 and Pirb/ mice (n = 10–14 per group). Although the time courses and augmentation magnitudes of the phosphorylation of p38 and Erk 
were not grossly different between wild-type and Pirb/ B-1 cells (A–C), phosphorylation of NF-B p65RelA was markedly augmented in Pirb/ B-1 
cells (A and D). The intensity for each band was estimated by densitometric scanning with normalization as to loading control. Data are shown as  
means ± SEM of three separate experiments. *, P < 0.05.JEM VOL. 206, August 31, 2009 
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As is well known, Btk is a critical kinase for the develop-
ment and function of B cells, including B-1 cells, by assur-
ing antigen receptor signaling, as has been demonstrated in 
immunocompromised Xid mice and human X-linked agam-
maglobulinemia, in which Btk is dysfunctional (Bradley et al., 
1994; Hashimoto et al., 1996). Our current finding that Btk 
is a critical link between the TLR9 cascade and the PIR-B–
mediated regulatory loop, particularly in B-1 cells expressing 
abundant PIR-B (Fig. S3 A), provides an insight into the 
mechanism underlying crosstalk of the innate immune system 
with ITIM-harboring receptors.
Given that PIR-B might be a negative regulator for 
TLR9 in B-1 cells, PIR-B–mediated inhibition of TLR9 ac-
tivation could become potentially harmful for host mammals 
if their immune system should engage with invading patho-
gens that otherwise would cause serious infectious diseases. 
Therefore, it is expected that this regulatory system might be 
tightly controlled during the course of the capture, sensing, 
activation. PIR-B is constitutively tyrosine phosphorylated   
at the ITIMs and associates with SHP-1 (Ho et al., 1999; 
Kubagawa et al., 1999; Maeda et al., 1999), which is critical 
for maintaining steady-state levels of intracellular phosphoty-
rosylated proteins. In this study, we found a novel and im-
mediately initiated regulatory circuit for TLR9, namely that 
PIR-B phosphorylation is immediately augmented by TLR9-
initiated Lyn activation, and the concomitant enhancement 
of SHP-1 recruitment to augmented phospho-ITIMs of PIR-B 
leads to Btk dephosphorylation, which then attenuates the 
phosphorylation  level  of  NF-B  p65RelA.  The  molecular 
mechanism for the TLR9-initiated Lyn activation, which aug-
ments Btk phosphorylation, is currently not known. Interest-
ingly, on the other hand, SHP-1 has recently been demonstrated 
to be a critical regulator for type I interferon production by 
macrophages and dendritic cells through inhibition of IRAK1 
activation downstream of TLR4 (An et al., 2008), whereas 
augmented IRAK1 activation is not observed in CpG-B–
stimulated Pirb/ B-1 cells (Fig. S5), suggesting that B-1 cells 
preferentially use Btk as a key intersecting molecule for the in-
hibitory circuit.
Recent  studies  have  shown  that  Btk  is  an  important 
mediator for the TLR9 cascade in addition to MyD88 and 
TRAF (Doyle et al., 2007; Gilliet et al., 2008). Btk is re-
quired for NF-B activation, participating in the pathway 
leading to increased phosphorylation of p65RelA activated 
by TLR8 and TLR9 (Doyle et al., 2007; Lee et al., 2008). 
Figure 7.  Phosphorylation of Btk but not Syk is markedly up-reg-
ulated upon CpG-B stimulation of Pirb/ B-1 cells. (A–C) Peritoneal 
B-1 cells from B6 and Pirb/ mice (n = 10–14 per group) were stimu-
lated with 1 µM CpG-B and subjected to immunoblot analysis for visual-
ization of phospho-Syk and phospho-Btk (A), which was estimated by 
densitometric scanning with normalization as to actin (B and C). Data are 
shown as means ± SEM of three separate experiments. *, P < 0.05.
Figure 8.  CpG-B–induced phosphorylation of Btk and NF-B 
p65RelA in peritoneal B-1 cells is down-regulated by Src family 
kinase inhibitors. (A–C) Peritoneal B-1 cells from wild-type B6 mice (n = 
12) were treated with 10 µM SU6656 or PP2 for 30 min before stimula-
tion with 1 µM CpG-B. 5 min later, cell lysates were subjected to immuno-
blot analysis to visualize the phosphorylation of Btk (top), NF-B  
p65RelA (middle), and loading control -actin (bottom; A). The phos-
phorylation levels of Btk and p65RelA were estimated by densitometric 
scanning with normalization as to actin and are depicted as bar graphs  
(B and C). Data are representative of three separate experiments with 
similar results.1980 PIR-B REGULATES TLR9-INDUCED BTK–NF-B CASCADE | Kubo et al.
basement membranes of glomeruli. Considering these obser-
vations, it may increasingly become important to manipulate 
the PIR-B–mediated inhibitory system in the regulation of 
autoimmune diseases while maintaining the integrity of TLR9-
mediated microbial sensing, in such cases as rheumatoid ar-
thritis (Newkirk, 2002). Understanding of the PIR-B system 
in B-1 cells may lead to the development of novel and effec-
tive ways toward controlling autoimmune diseases.
MATERIALS AND METHODS
Mice. C57BL/6 (B6) mice were purchased from Charles River Laborato-
ries. Pirb/ mice were generated (Ujike et al., 2002) and backcrossed with 
B6 mice for 12 generations. Pirb/Faslpr mice were generated by crossing 
B6.Faslpr mice (C57BL/6J Jms Slc-lpr/lpr; The Jackson Laboratory) with 
B6.Pirb/ mice and by intercrossing between the littermates. TLR9-deficient 
(Tlr9/) mice were purchased from Oriental BioService, Inc. Mice were 
maintained and bred in the Animal Facility of the Institute of Development, 
Aging, and Cancer, Tohoku University, an environmentally controlled and 
specific pathogen-free facility, according to guidelines for experimental ani-
mals defined by the university, and animal protocols were reviewed and ap-
proved by the Animal Studies Committee of the university. All experiments 
were performed on 6–50-wk-old age-matched male and female mice.
Reagents and antibodies. LPS (B8) was purchased from Sigma-Aldrich. 
Poly(I:C) and ssRNA/LyoVec were obtained from InvivoGen. Anti-IgM 
F(ab)2 was purchased from Invitrogen. Phosphothioate–CpG-B oligode-
oxynucleotide (ODN1826; 5-TCCATGACGTTCCTGACGTT-3) and 
phosphothioate-GpC (5-TCCATGAGCTTCCTGAGCTT-3) were syn-
thesized by Hokkaido System Science Co., Ltd. Src kinase inhibitors SU6656 
and PP2 were obtained from EMD. Antibodies to phospho-Syk (Tyr352), 
Syk, Lyn, phospho–p44/42 MAPK (Thr202/Tyr204 and D13.14.4E), phos-
pho-p38 (Thr180/Tyr182), p38 (5F11), phospho–NF-kB p65 (Ser536), and 
NF-B p65 were obtained from Cell Signaling Technology. Phospho-Btk 
(Tyr550) antibody was obtained from Abcam. Antibodies to Btk, Erk, PIR-
B (p91), anti-IRAK1, anti–mouse monoclonal Btk (E-9), and SHP-1 were 
purchased from Santa Cruz Biotechnology, Inc. The horseradish peroxidase 
(HRP)–conjugated antiphosphotyrosine mAb (RC20) was purchased from 
BD. The antibody to -actin was obtained from Sigma-Aldrich.
Cell separation. For separation of splenic B cells, B220+ cells were purified 
with a magnetic-activated cell sorter (MACS; Miltenyi Biotec). For prepara-
tion of peritoneal B-1 cells, peritoneal cells were isolated by washing of the 
peritoneal cavity with ice-cold RPMI 1640 containing 10% FCS. Peritoneal 
cells were first blocked with anti–mouse FcR mAb (2.4G2; BD) and then 
stained with allophycocyanin (APC)-labeled anti-B220 (RA3-6B2; BD) and 
FITC-labeled anti-CD11b (M1/70; BD) mAbs, and B220+CD11b+ cells 
were sorted using a FACSAria (BD). The purity of the sorted populations 
was consistently >95%, as determined by the B220+CD11b+ phenotype. 
Bone marrow cells from femurs were cultured in -MEM containing 10% 
FCS and 20 ng/ml M-CSF (PeproTech) at 37°C. After 7 d, the adherent 
cells were used as bone marrow–derived macrophages (BMMs).
Proliferation assay. 105 splenic B cells per well and 2.5 × 104 peritoneal 
B-1 cells per well were cultured in 96-well flat plates (Corning) with RPMI 
1640 containing 10% FCS, 1 mM sodium pyruvate, and supplemented anti-
biotics. The cells were activated with the reagents described in Reagents and 
antibodies.  After  48  h  of  stimulation,  proliferation  was  determined  as 
[3H]thymidine uptake.
Measurement of antibodies and a cytokine. 5 × 104 peritoneal B-1 cells 
per well were cultured in 96-well flat plates with or without stimulants. The 
supernatants of 20–72-h-cultured peritoneal B-1 cells were collected, and the 
amounts of anti-dsDNA antibodies, RF, IgM, and IL-10 were determined 
processing,  and  elimination  of  virulent  microbes.  How  is 
PIR-B–initiated TLR9 regulation controlled? Although we 
do not currently have an answer to this question, it is con-
ceivable that cell-surface expression of PIR-B might be down-
regulated or the expression of PIR-A with possibly the 
opposite function, namely the activation of TLR9, might be 
up-regulated, or both. Another possibility is that spatial com-
munication between PIR-B and TLR9 on, or near, the cell 
membrane might be uncoupled during serious infections by 
means of any unknown intracellular mechanism that controls 
the dynamics of endosomal/lysosomal TLR9 as well as the 
dynamics of PIR-B. It may be possible that PIR-B on plasma 
membrane could translocate partially to the endosomal/lyso-
somal compartment of B-1 cells upon CpG stimulation. Our 
preliminary confocal laser-scanning microscopic analysis of 
B-1 cells stimulated with CpG suggests that it could be the 
case (Fig. S6). Such translocation may account for, at least 
partly, the reason why endosomal/lysosomal TLR9 can com-
municate intimately with PIR-B in terms of CpG-initiated, 
TLR9-mediated signaling and may imply a presence of any 
uncoupling mechanism for the TLR9–PIR-B communica-
tion. On the other hand, although preceding studies have 
demonstrated  the  critical  roles  of  inhibition  mediated  by 
PIR-B in the maintenance of immune homeostasis (Wheadon 
et al., 2002; Ujike et al., 2002; Nakamura et al., 2004; Pereira 
et al., 2004; Zhang et al., 2005; Masuda et al., 2007), the 
function of the activating counterpart, PIR-A, remains to be 
determined, but it also can bind to MHC class I molecules 
(Nakamura et al., 2004). Control mechanisms for balanced, 
or in some cases unbalanced, PIR-B and PIR-A gene expres-
sion are also not known. One notable observation is that PIR-B 
expression on activated B cells is reduced by IL-4 (Rudge   
et al., 2002). Another interesting notion is that PIR-A expres-
sion on host dendritic cells is significantly augmented during 
the  induction  phase  of  experimental  acute  graft-versus- 
disease induced in Pirb/ mice (Nakamura et al., 2004). Ob-
viously, we need more precise knowledge on the regulation 
of PIR-A and PIR-B, and the spatial communication be-
tween membrane PIR-B and endosomal/lysosomal TLR9.
CD5+ B-1 cells are considered to be involved in some 
autoimmune diseases in which RF is frequently detected or 
RF production is directly coupled to the disease (Hardy et al., 
1987; Sowden et al., 1987; Youinou et al., 1990). Also, RF+ 
B cells are effectively activated via the IgG2a–chromatin im-
mune complex and synergistic stimulation of TLR9-mediated 
signaling (Leadbetter et al., 2002). It is known that RF can bind 
to anti-dsDNA autoantibodies and can form immune com-
plexes (Izui and Eisenberg, 1980). Also, it has been reported 
that RF itself has cryoglobulin activity and causes glomerulo-
nephritis without any other additional factors (Gyotoku et al., 
1987). Our observations on glomerulonephritis in Pirb/Faslpr 
mice with markedly and specifically elevated IgM- and IgG-RF 
productions, but not other autoantibodies examined, suggest 
that IgM- and IgG-RF autoantibodies, namely anti-IgG Fc 
antibodies, are factors that worsen the disease, presumably by 
accelerating the deposition of IgG autoantibodies against JEM VOL. 206, August 31, 2009 
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through a graded ethanol series. After washing with distilled water, sections 
were incubated with trypsin (Nichirei) for 50 min at 37°C and washed three 
times with PBS. Sections were incubated with Alexa Fluor 488–conjugated 
anti–mouse IgG, IgM (Invitrogen), goat IgG fraction to mouse complement 
C3 (Cappel; MP Biomedicals), or Alexa Fluor 488–conjugated anti–goat 
IgG (Invitrogen). To detect antinuclear antibodies in sera, HEp2 cell plates 
(FLUORO HEPANA test; MBL International) were stained with sera from 
B6 Pirb/, Faslpr, Pirb/Faslpr, and Fcgr2b/Faslpr (Yajima et al., 2003) mice 
at different dilutions, and detected with FITC-conjugated anti–mouse IgG 
(Cappel; MP Biomedicals). Samples were examined under microscopes (BX50 
[Olympus] and VB-7000 [Keyence]).
Renal function test. Serum from mice of each strain at 40 wk of age was 
collected, and the amounts of blood urea nitrogen and creatinine were de-
termined with a dry chemistry analyzer (Fujifilm).
Confocal laser-scanning microscopic analysis. MACS-sorted perito-
neal B-1 cells (CD3, F4/80, CD23, and IgM+) from B6 mice were cul-
tured with Cy5-conjugated CpG-B (ODN1826; Nihon Gene Research 
Laboratories Inc.) and LysoTracker Green DND-26 (Invitrogen) for 30 min. 
After fixation with Cytofix/Cytoperm, cells were permeabilized with Perm/
Wash and stained with biotin-conjugated anti–mouse PIR-A/B (6C1) or   
rat IgG1 isotype control (BD) and Alexa Fluor 546–conjugated streptavi-
din (Invitrogen). Samples were examined under a microscope (Fluoview 
FV1000; Olympus).
Statistical analysis. Statistical analyses were performed using two-way 
analysis of variance or Student’s t test. P < 0.05 is considered as statisti-
cally significant.
Online supplemental material. Fig. S1 presents additional data showing 
that PIR-B deletion leads to renal dysfunction when combined with the 
Faslpr mutation but does not have an impact on arthritis development, or anti-
nuclear, anti–SS-B/La, and anti–2-GPI autoantibody production. Fig. S2 
shows diminishment of peritoneal B cells in Pirb/ mice by repeated water 
injection. Fig. S3 shows that peritoneal B-1 cells express much more PIR-B 
than splenic B-2 cells, that TLR9 expression does not differ between B-1 
and B-2 cells, and that Btk expression is higher in B-1 than B-2 cells. Fig. S4 
shows that PIR-A expression is not detected on B-1 cells and that TLR9 
expression does not change. Fig. S5 shows that the IRAK1 degradation level 
was not significantly altered in PIR-B–deficient B-1 cells. Fig. S6 shows that 
PIR-B can translocate into the endolysosomal compartment after CpG-B 
stimulation of B-1 cells. Table S1 presents hematocrit values for Pirb/ and 
Pirb/Faslpr mice. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20082392/DC1.
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